Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
André J. Scheen. (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 17:4, pages 485-496.
Read now
Read now
Melanie Davies, Sudesna Chatterjee & Kamlesh Khunti. (2016) The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology: Advances and Applications 8, pages 61-81.
Read now
Read now
John E. Anderson, Vivian T. Thieu, Kristina S. Boye, Ryan T. Hietpas & Luis-Emilio Garcia-Perez. (2016) Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. Postgraduate Medicine 128:8, pages 810-821.
Read now
Read now
André J. Scheen. (2016) Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Review of Clinical Pharmacology 9:3, pages 385-399.
Read now
Read now
Articles from other publishers (13)
In Bok An, Mi Sun Byun, Sang In Yang, Yuri Choi, Jung Won Woo, Hak Chul Jang & Young Chul Sung. (2020)
A glycosylated
Fc
‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
. Diabetes, Obesity and Metabolism 22:8, pages 1455-1468.
Crossref
Crossref
Martin Haluzík. (2020) Incretin-based treatment of diabetes and cardiovascular complications. Vnitřní lékařství 66:2, pages 74-80.
Crossref
Crossref
L. I Bugaeva, E. A Kuzubova, M. V. Maltsev, E. B Lavrova, I. N Tyurenkov, D. V Kurkin, E. V. Volotova, D. A Bakulin & G. P Dudchenko. (2020) THE INFLUENCE OF THE AGONIST OF RECEPTORS GPR-119 (COMPOUNDS ZB-16) ON SPERMATOGENESIS AND FERTILIZATION FUNCTION OF MALE RATS. Journal of Volgograd State Medical University 17:3, pages 103-106.
Crossref
Crossref
Marco Cavaco, Miguel A. R. B. Castanho & Vera Neves. (2018) Peptibodies: An elegant solution for a long-standing problem. Peptide Science 110:1, pages e23095.
Crossref
Crossref
Luca Di Lullo, Michela Mangano, Claudio Ronco, Vincenzo Barbera, Antonio De Pascalis, Antonio Bellasi, Domenico Russo, Biagio Di Iorio & Mario Cozzolino. (2017) The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S295-S305.
Crossref
Crossref
Marina V. Shestakova & Ekaterina A. Yudovich. (2017) Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies. Diabetes mellitus 20:3, pages 220-230.
Crossref
Crossref
Keith C. Ferdinand, Fady T. Botros, Charles M. Atisso & Philip T. Sager. (2016) Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Johan Jendle, George Grunberger, Thomas Blevins, Francesco Giorgino, Ryan T. Hietpas & Fady T. Botros. (2016) Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes/Metabolism Research and Reviews 32:8, pages 776-790.
Crossref
Crossref
Caslin A. Gilroy, Kelli M. Luginbuhl & Ashutosh Chilkoti. (2016) Controlled release of biologics for the treatment of type 2 diabetes. Journal of Controlled Release 240, pages 151-164.
Crossref
Crossref
G. E. Umpierrez, K. M. Pantalone, A. Y. M. Kwan, A. G. Zimmermann, N. Zhang & L. Fernández Landó. (2016) Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment. Diabetes, Obesity and Metabolism 18:6, pages 615-622.
Crossref
Crossref
Sten Madsbad. (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes, Obesity and Metabolism 18:4, pages 317-332.
Crossref
Crossref
Yu Mi KangChang Hee Jung. (2016) Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinology and Metabolism 31:2, pages 258.
Crossref
Crossref
Cyrus V. Desouza, Namita Gupta & Anery Patel. (2015) Cardiometabolic Effects of a New Class of Antidiabetic Agents. Clinical Therapeutics 37:6, pages 1178-1194.
Crossref
Crossref